Cargando…
Imiquimod 3.75% for field‐directed therapy of actinic keratosis: results of a prospective case‐series study in Greece
BACKGROUND: Imiquimod 3.75% is a field‐directed treatment for actinic keratosis that can detect and treat clinical and subclinical lesions across an entire sun‐exposed field. The detection of subclinical lesions is evidenced by an increase in lesions to the maximum lesion count during treatment (L (...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850341/ https://www.ncbi.nlm.nih.gov/pubmed/30779341 http://dx.doi.org/10.1111/ijd.14397 |